OmniZare Imaging Forms Medical Advisory Board
Drs. William Chin and Edward Legare Lend Expertise to New Medical Imaging Technology Company
Boston, September 9, 2024 – OmniZare Imaging, an innovative new technology company applying its expertise to revolutionize medical imaging, today announced that Drs. William Chin and Edward Legare have joined its Medical Advisory Board. Co-founded by Eric Giler and Dr. Andre Kurs, OmniZare aims to democratize high-quality medical imaging, improve medical outcomes, and reduce mortality by facilitating early diagnosis and detection of treatable conditions.
OmniZare has developed an imaging platform consisting of: purpose-built sensing hardware; and cloud software to analyze and interpret the data. The company uses Dielectric Tomography which produces three-dimensional millimeter-scale resolution of the ultra- wideband dielectric and magnetic properties of biological tissue. To-date, the company has developed:
Cranial scanner to diagnose and screen for stroke, tumors, and traumatic brain injury
Handheld scanner for liver conditions and traumatic injuries
Extremity scanner to monitor and manage age-related muscle and bone diseases
Breast imaging capabilities
“OmniZare has assembled a leadership team with deep expertise and a proven track record in management, technology, product development, and intellectual property strategy. Bill and Ned bring their valuable medical opinions and experience to the team,” said Eric Giler, Co-Founder of OmniZare. “Bill has tremendous industry experience and deep knowledge of medicine. Ned brings his patient connections and understanding of the struggle patients face when trying to get a proper imaging diagnosis quickly and affordably.”
Dr. William Chin is the Bertarelli Professor of Translational Medical Science and Medicine Emeritus, Harvard Medical School (HMS) and a former executive leader in pharmaceutical R&D. He is a former Senior Vice President and Head of Global Research at Eli Lilly and Company; and Executive Vice President and Chief, Medical Officer, PhRMA
He has also served as: Executive Dean for Research, HMS; Chief of the Division of Genetics, Brigham and Women’s Hospital and HMS; and Investigator, Howard Hughes Medical Institute. Dr. Chin is a world-renowned scientist who has performed basic science research in the hormonal regulation of gene expression. Dr. Chin received his AB in Chemistry from Columbia University, and holds a MD from Harvard Medical School and is Board-certified in Internal Medicine and Endocrinology.
“OmniZare’s technology is a game-changer in the world of medical imaging,” explained Dr. Chin. “By radically reducing cost and form factor, the company will help to revolutionize the ways we use imaging at the point of care, in emergencies, and throughout the developing world.”
Dr. Edward Legare brings his extensive internal medicine and medical leadership expertise to OmniZare. His contributions help shape medical policies and strategies to improve patient care and outcomes.
Since 1995, Dr. Legare has been practicing internal medicine at Mass General Brigham. In 1997, Dr. Legare co-founded Newton-Wellesley Primary Care, where he continues to provide comprehensive primary care services.
Dr. Legare served as a Major in the US Army, where he completed his internship and residency from 1989 to 1995. In addition to his clinical roles, Dr. Legare is a Trustee at Newton-Wellesley Hospital. Dr. Legare earned his BS degree from the University of Notre Dame and his Doctor of Medicine degree from Tufts University School of Medicine.
“As a clinician, I’m very excited about OmniZare’s approach to imaging,” said Dr. Legare. “Their unique technology will provide new opportunities to make imaging widely available at the point of care, resulting in better outcomes and more proactive approaches to treatment.”
About OmniZare Imaging
OmniZare is an innovative technology company applying its expertise to revolutionize medical imaging. It combines groundbreaking technical insight with recent technological advances, increasing processing power, and price reductions in components to develop imaging solutions that are 100x less expensive and 10,000x safer than existing solutions.
Using dielectric tomography to measure the electrical properties of human tissue, it can produce a new solution that produces highly accurate images. OmniZare’s technology is well-positioned to capture a significant portion of the medical imaging market, which is projected to reach more than $60B by 2030.